Heat shock proteins gp96 as immunogens in cancer patients

Figures & data

Table I.  Increased frequency of anti-tumour T and NK cells in patients vaccinated with autologous tumour-derived HSPPC-96.*

	No of responding^# patients/no of patients tested
Trial	T-cells	NK-cells
Patients with metastatic melanoma vaccinated with HSPPC-96 only	11/23 (48%)	ND
Patients with metastatic melanoma vaccinated with HSPPC-96 + GM-CSF + IFNα	5/16 (32%)	12/18 (66%)
Patients with liver metastases of CRC vaccinated with HSPPC-96 only	16/29 (55%)	18/26 (69%)

*HSPPC-96 = heat shock protein peptide complex 96 or Oncophage®.

^#Responding patients were those showing a statistically significant increase in frequency of T-cells recognizing HLA-restricted tumour antigens or of NK-cells recognizing and killing tumour cells after the first cycle (four injections) of vaccination.

Table II.  Association between clinical response, T-cell response and HLA/melanoma associated antigen (MAA) expression by the original tumour.

Features	No of patients	Clinical response	T-cell response
High HLA/MAA*	10	7 SD, 3 PRO	7/10
Low HLA/MAA	6	1 SD, 5 PRO	1/6

*Tumour expressing at least 50% of cells positive for class I HLA and for at least one melanoma antigen (gp100 and/or MelanoA/MART1).